Michelle Xia

Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial

Xiangyu Gao, Nong Xu, Ziyu Li et al. · The Lancet Oncology · 2023 · 171 citations

Oncology, Medicine, Advanced Solid Tumours +8

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China

Anwen Xiong, Lei Wang, Jianhua Chen et al. · The Lancet · 2025 · 90 citations

Medicine, Immunology, Pathology +6

AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial

Yuanyuan Zhao, Gang Chen, Jianhua Chen et al. · EClinicalMedicine · 2023 · 75 citations · Full text

Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China

Xiaohua Wu, Yang Sun, Hongying Yang et al. · The Lancet · 2024 · 73 citations

Metastatic Cervical Cancer, Cervical Cancer, Placebo-controlled Phase 3 +9

First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial

Lin Shen, Yanqiao Zhang, Ziyu Li et al. · Nature Medicine · 2025 · 59 citations

Esophageal Cancer, Gastrointestinal Oncology, Medicine +8